ALHC vs. CYTK: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALHC and CYTK, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
With ALHC at 3.03 billion USD and CYTK at 3.74 billion USD, their market capitalizations sit in the same ballpark.
ALHC’s beta of 1.33 points to much larger expected swings compared to CYTK’s calmer 0.81, suggesting both higher upside and downside potential.
Symbol | ALHC | CYTK |
---|---|---|
Company Name | Alignment Healthcare, Inc. | Cytokinetics, Incorporated |
Country | US | US |
Sector | Healthcare | Healthcare |
Industry | Medical - Healthcare Plans | Biotechnology |
CEO | Mr. John E. Kao | Mr. Robert I. Blum |
Price | 15.33 USD | 31.31 USD |
Market Cap | 3.03 billion USD | 3.74 billion USD |
Beta | 1.33 | 0.81 |
Exchange | NASDAQ | NASDAQ |
IPO Date | March 26, 2021 | April 30, 2004 |
ADR | No | No |
Performance Comparison
This chart compares the performance of ALHC and CYTK over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALHC and CYTK based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- Neither ALHC nor CYTK turned a profit—both carry negative P/E ratios of -32.75 and -6.03, underscoring continued losses that pressure their valuations.
- ALHC posts a negative forward PEG of -1.11, hinting at anticipated earnings decline, whereas CYTK at 10.57 has projections for stable or growing earnings.
- CYTK carries a sub-zero price-to-book ratio of -13.93, indicating negative equity. In contrast, ALHC (P/B 27.45) has positive book value.
- CYTK reports a negative Price-to-Free Cash Flow ratio of -9.14, showing a cash flow shortfall that could threaten its operational sustainability, while ALHC at 159.00 maintains positive cash flow.
Symbol | ALHC | CYTK |
---|---|---|
Price-to-Earnings Ratio (P/E, TTM) | -32.75 | -6.03 |
Forward PEG Ratio (TTM) | -1.11 | 10.57 |
Price-to-Sales Ratio (P/S, TTM) | 1.01 | 194.57 |
Price-to-Book Ratio (P/B, TTM) | 27.45 | -13.93 |
Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 159.00 | -9.14 |
EV-to-EBITDA (TTM) | -64.47 | -8.64 |
EV-to-Sales (TTM) | 0.86 | 231.90 |
EV-to-Free Cash Flow (TTM) | 136.01 | -10.89 |
Dividend Comparison
Neither ALHC nor CYTK currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
Symbol | ALHC | CYTK |
---|---|---|
Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALHC and CYTK, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- CYTK has negative equity (debt-to-equity ratio -2.97), suggesting asset shortfalls, whereas ALHC at 0.07 preserves healthier equity coverage.
- Both ALHC and CYTK report negative interest coverage ratios (-2.98, -6.14), meaning EBIT itself is negative—neither can cover interest, a critical solvency warning.
Symbol | ALHC | CYTK |
---|---|---|
Current Ratio (TTM) | 1.69 | 5.99 |
Quick Ratio (TTM) | 1.69 | 5.99 |
Debt-to-Equity Ratio (TTM) | 0.07 | -2.97 |
Debt-to-Assets Ratio (TTM) | 0.01 | 0.63 |
Interest Coverage Ratio (TTM) | -2.98 | -6.14 |